| Literature DB >> 35115322 |
Marcia McDougall1, Bruce Guthrie2, Arthur Doyle3, Alan Timmins4, Meghan Bateson5, Emily Ridley6, Gordon Drummond7, Thenmalar Vadiveloo8.
Abstract
BACKGROUND: National Institute for Health and Care Excellence (NICE) guidelines on intravenous fluid prescribing for adults in hospital, issued in 2013, advised less use of 0.9% sodium chloride than current practice, provided a logical system for prescribing and suggested further study of electrolyte abnormalities. AIMS: To describe the steps taken to establish and monitor guideline introduction and to assess effects on clinical biochemistry results, in a general hospital setting.Entities:
Keywords: clinical practice guidelines; health professions education; quality improvement
Mesh:
Substances:
Year: 2022 PMID: 35115322 PMCID: PMC8814811 DOI: 10.1136/bmjoq-2021-001636
Source DB: PubMed Journal: BMJ Open Qual ISSN: 2399-6641
Figure 1Monthly fluid use over the study period. (A) Changing use of total fluid, 0.9% sodium chloride, balanced electrolyte solutions (Hartmann’s solution and Plasma-Lyte) and the introduction of 0.18% sodium chloride and 4% glucose as a maintenance fluid. (B) Changes in the pattern of maintenance fluid use and potassium supplements over the same period. Before time mark B, all fluids containing potassium are shown, that is, 0.9% sodium chloride with potassium and 5% glucose with potassium. Note the different scale for fluid volume. Time marks apply to both panels and indicate: A: start of fluid education, B: Guidelines introduced and C: sustained campaign to encourage 0.18% sodium chloride and 4% glucose solutions with potassium.
Clinical measures before and after guideline introduction
| Feature | Before guidelines | After guidelines | ||||||
| Case numbers | Cases | % | 5%–95% CI | Case numbers | Cases | % | 5%–95% CI | |
| Entire population | ||||||||
| Any abnormality | 15 639 | 2248 | 14.4 | 13.8 to 14.9 | 17 033 | 2037 | 12.0 | 11.5 to 12.5 |
| Acidosis | 1164 | 7.4 | 7.0 to 7.9 | 813 | 4.8* | 4.5 to 5.1 | ||
| Hyponatraemia | 155 | 1.0 | 1.0 to 1.3 | 185 | 1.1 | 0.9 to 1.3 | ||
| Hypernatraemia | 146 | 0.9 | 0.9 to 1.3 | 112 | 0.7 | 0.7 to 1.0 | ||
| Hypokalaemia | 537 | 3.4 | 3.6 to 4.3 | 542 | 3.2 | 3.6 to 4.3 | ||
| Hyperkalaemia | 246 | 1.6 | 1.6 to 2.1 | 385 | 2.3* | 2.6 to 3.2 | ||
| Mortality | 13 592 | 1311 | 9.6 | 9.2 to 10.0 | 13 144 | 1261 | 9.6 | 9.1 to 10.1 |
| Length of stay (mean) | 7.7 | 9.2 | ||||||
| AKI | 10 541 | 12 862 | ||||||
| Stage 1 | 707 | 6.7 | 6.2 to 7.2 | 1160 | 9.0* | 8.5 to 9.5 | ||
| Stage 2 | 151 | 1.4 | 1.2 to 1.7 | 308 | 2.4* | 2.1 to 2.7 | ||
| Stage 3 | 151 | 1.4 | 1.2 to 1.7 | 256 | 2.0 | 1.8 to 2.3 | ||
| Emergency patients (medical, general and orthopaedic surgery) | ||||||||
| Any abnormality | 10 701 | 1867 | 17.4 | 16.7 to 18.2 | 12 757 | 1690 | 13.2 | 12.7 to 13.8 |
| Acidosis | 923 | 8.6 | 8.1 to 9.2 | 653 | 5.1 | 4.8 to 5.5 | ||
| Hyponatraemia | 126 | 1.2 | 1 to 1.4 | 132 | 1.0 | 0.8 to 1.2 | ||
| Hypernatraemia | 143 | 1.3 | 1.1 to 1.6 | 110 | 0.9 | 0.7 to 1.0 | ||
| Hypokalaemia | 487 | 4.6 | 4.2 to 5.0 | 510 | 4.0 | 3.7 to 4.4 | ||
| Hyperkalaemia | 188 | 1.8 | 1.5 to 2.0 | 285 | 2.2 | 2.0 to 2.5 | ||
| Mortality | 8654 | 1288 | 14.9 | 14.1 to 15.6 | 8868 | 1234 | 13.9 | 13.2 to 14.7 |
| Length of stay (mean) | 8.9 | 7.8 | ||||||
| AKI | 6873 | 8868 | ||||||
| Stage 1 | 514 | 7.5 | 6.9 to 8.1 | 807 | 9.1 | 8.5 to 9.7 | ||
| Stage 2 | 116 | 1.7 | 1.4 to 2.0 | 209 | 2.4 | 2.1 to 2.7 | ||
| Stage 3 | 146 | 2.1 | 1.8 to 2.5 | 223 | 2.5 | 2.2 to 2.9 | ||
| Elective patients (general and orthopaedic surgery) | ||||||||
| Any abnormality | 4938 | 381 | 7.7 | 7.0 to 8.5 | 4276 | 347 | 8.1 | 7.3 to 9.0 |
| Acidosis | 241 | 4.9 | 4.3 to 5.5 | 160 | 3.7 | 3.2 to 4.4 | ||
| Hyponatraemia | 29 | 0.1 | 0 to 0.1 | 53 | 1.2 | 0.9 to 1.6 | ||
| Hypernatraemia | 3 | 0.0 | 2 | 0.0 | 0 to 0.2 | |||
| Hypokalaemia | 50 | 1.0 | 0.8 to 1.3 | 32 | 0.7 | 0.5 to 1.1 | ||
| Hyperkalaemia | 58 | 1.2 | 1.0 to 1.5 | 100 | 2.3 | 1.9 to 2.8 | ||
| Mortality | 4938 | 23 | 0.5 | 0.3 to 0.7 | 4276 | 27 | 0.6 | 0.4 to 0.9 |
| Length of stay (mean) | 4.3 | 4.4 | ||||||
| AKI | 3668 | 3994 | ||||||
| Stage 1 | 193 | 5.3 | 4.6 to 6.0 | 353 | 4.0 | 3.6 to 4.4 | ||
| Stage 2 | 35 | 0.9 | 0.6 to 1.3 | 99 | 1.1 | 0.9 to 1.4 | ||
| Stage 3 | 5 | 0.1 | 0 to 0.3 | 33 | 0.4 | 0.3 to 0.5 | ||
*For the entire population, significant change, p<0.0002. Statistical analysis of differences in the subgroups was not carried out.
AKI, acute kidney injury.
Figure 2Association between the use of 0.9% sodium chloride (solid line) and the quarterly incidence of acidosis (filled circles), over the early study period. Time marks indicate: A: start of fluid education and B: guidelines introduced.
Figure 3Proportional usage of intravenous crystalloid fluids in Scottish health boards, ranked in decreasing order of proportional use of 0.9% sodium chloride, for the financial years 2017 and 2018. The effect of implementing the NICE guidelines is clear, comparing NHS Fife to the pattern of use in other health boards. Note the greater use of 0.18% sodium chloride and 4% glucose, the limited use of 5% glucose and a smaller proportion of use of 0.9% sodium chloride, indicating maintenance prescribing based on the NICE guidelines. The two columns adjacent to NHS Fife show the start of similar prescribing in these hospital boards. NHS, National Health Service; NICE, National Institue for Health and Care Excellence.